Aspirin Rival Cuts Repeat Heart Attack Risk by 23%, Trial Analysis Finds

Why compare them with aspirin at all?

Aspirin has a well-known downside: it raises bleeding risk, including bleeding in the stomach. That's why researchers pooled data from seven trials comparing a single P2Y12 medicine against aspirin alone, all in people who already had the disease.

The results point in one direction on effectiveness:

• 12% lower relative risk of the combined outcome — heart-related death, heart attack or stroke — for the P2Y12 group.
• 23% fewer heart attacks in the P2Y12 group, the main driver of that overall benefit.
• No clear reduction in death or stroke when researchers examined each separately.

One caveat worth knowing: these percentages compare the two groups as wholes. They don't tell you how much any individual patient's risk would fall.

What about safety?

Major bleeding occurred at broadly similar rates with both treatments. But two specific bleeding types favored the newer drugs: digestive-system bleeding and bleeding strokes were less common among people taking P2Y12 medicines.

For context, that safety profile matters as much as the effectiveness numbers. A clot-preventer that merely shifts harm from clots to bleeds wouldn't be an advance — and this analysis suggests P2Y12 drugs don't do that.

Does this mean everyone should switch?

No, and the researchers are careful on this point. The study tested specific treatments in people with established coronary artery disease — not medicines for healthy people hoping to prevent a first heart attack. It doesn't touch primary prevention at all.

Individual circumstances still drive the decision. Doctors need to weigh a patient's past heart problems, bleeding risk, other medications and how they respond to treatment.

The study's own authors' practical message is blunt: people taking aspirin should not stop it or switch drugs without medical advice, especially after a heart attack or stent placement.

What comes next?

The findings point toward more personalized heart care rather than one pill for everyone. Aspirin may not always be the best long-term choice for someone whose heart arteries are already blocked or narrowed, but the case isn't closed.

Two gaps remain. The trial data covers roughly two years of follow-up, so longer observation could shift the picture. And the analysis pooled P2Y12 drugs rather than comparing clopidogrel and ticagrelor against each other — head-to-head studies could clarify exactly which patients benefit most.

For now, the takeaway is a measured one: aspirin finally has a serious, evidence-backed rival for long-term use in heart patients, and it may beat the old standard where it counts most — preventing the next heart attack.